Moscow, Russia, 3rd November 2020–CooperVision is pleased to announce the Brilliant Futures™ Myopia Management Programme, featuring the innovative MiSight® 1 day contact lens, is now available in the Russian Federation for the management of childhood myopia.
“The prevalence of childhood myopia in the World has more than doubled over the past 50 years, and will double once more by 2050”1 comments Max Abramov, Myopia Programme Manager, CooperVision. “Many children are spending less time outdoors and more time learning via screen-based platforms, which may influence the development of myopia.2,3,4 It is vital to manage this progression early, and with urgency, to help protect future eye health. As global pioneers in this field, we have developed Brilliant Futures™ to help eye care practitioners and parents slow myopic progression in children.”
Brilliant Futures™ seeks to introduce a new standard of care for children with myopia. It provides inclusive practice, child and parent support to create the optimal environment for compliance, satisfaction, clinical outcomes and long-term loyalty. Brilliant Futures™ is built around MiSight® 1 day contact lenses, with ActivControl™ Technology, which have been clinically proven to slow the progression of myopia for children.5*
The programme features:
- Professional Accreditation Programme delivered through CooperVision’s online Learning Academy. The programme equips practitioners to understand, initiate and develop a myopia management practice ahead of gaining access to Brilliant Futures™.
- In-practice tools to help practitioners identify those children most at risk of developing myopia and sophisticated communication tools to aid the introduction and subsequent commitment to intervention.
- Information support to draw parents’ attention to myopia risks, possible solutions and help establish communication with specialists in clinical practices.
Myopic progression has been linked to significant eye-health and sight-threatening conditions later in life such as cataracts, retinal detachment, glaucoma and myopic maculopathy.6 The risk of these conditions multiplies as a prescription gets stronger.7,8
This is echoed in the seminal World Health Organization (WHO) 2015 report that declared “Myopia and high myopia are increasing globally at an alarming rate, with significant increases in the risks for vision impairment from pathologic conditions associated with high myopia.”9
According to recent studies, about 50% of the World’s population will become myopic by 2050 and 10% of them will have myopia more then five dioptres.1
“Myopia management is about going beyond vision correction and providing longer-term benefits to young patients,” said Indie Grewal, Optometrist and President of the British Contact Lens Association (BCLA). “This innovative approach has the potential to revolutionise clinical outcomes and can allow us to change the trajectory of childhood myopia in practice. We now have an opportunity to tackle myopia head-on and ultimately help young patients see well into the future.”
CooperVision’s research into MiSight® 1 day’s performance has been far reaching. The prospective, multi-centre, double-masked, randomised multi-year study enrolled 144 myopic children aged 8-12 years from Singapore, Canada, the United Kingdom and Portugal. Three-year peer-reviewed results published in Optometry and Vision Science in August 2019 indicated that use of MiSight® 1 day was shown to slow myopia progression by 59% on average as measured by mean cycloplegic spherical equivalent (SE) and 52% on average as measured by mean axial elongation of the eye.*5
The trial has continued with highly encouraging results reported for years four and five, in which the original control group was refitted into MiSight® 1 day with some children wearing the contact lens in their late teens.10
The MiSight® 1 day lens is already being successfully worn by thousands of myopic children in the UK and other parts of the world, including Australia, Canada and Spain.5 It has been recognised as one of the most innovative developments in eye health by the British Contact Lens Association and international industry media.
To learn more about the Brilliant Futures™ Myopia Management Programme, please visit coopervision.ru
*Compared to a single vision one-day lens over a three-year period.
CooperVision RUS LLC is not an organization engaged in training and educational activities that involves obtaining a document of education and / or qualification (diploma) in accordance with Federal law No. 273-FZ of 29.12.2012 " on education in the Russian Federation.
1 Holden BA, et al. Ophthalmology. 2016;123:1036–1042.
2 Wolffsohn J, et al. Cont Lens Anterior Eye. 2016;39:106–116
3 WHO. The impact of increasing prevalence of myopia and high myopia. A Report of the Joint World Health Organisation (2015). Available at: www.who.int/blindness/causes/MyopiaReportforWeb.pdf. Accessed August 2020
4 Gifford P & Gifford, K. Optom Vis Sci. 2016;93:336–343
5 Chamberlain P, et al. Optom Vis Sci. 2019;96:556–567
6 Tideman J, et al. JAMA Opthalmol. 2016;134:1355-1363
7 Flitcroft, D. Prog Retin Eye Res. 2012;31(6):622-60
8 Bourne R, et al. Lancet Glob Health. 2013;1(6):e339-49
9 The Impact of Myopia and High Myopia. Report of the Joint World Health Organization-Brien Holden Vision Institute Global Scientific Meeting on Myopia. University of New South Wales, Sydney, Australia. 16-18 March 2015
10 Chamberlain P, et al. Clinical evaluation of a dual-focus myopia control 1 day soft contact lens. 5-year results (2019 BCLA Clinical Conference & Exhibition).
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of daily disposable, two-week and monthly contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism, presbyopia and childhood myopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
CONTACT DETAILS: firstname.lastname@example.org
+7(800)200 77 44